PORTEC-4a Trial: A Comprehensive Review

Background and Rationale

Trial Design and Study Methodology

Trial Type

• Phase III, randomized, multicenter trial
• Conducted across multiple centers in the Netherlands (led by Leiden University Medical Center)
• Sponsor: Dutch Cancer Society (KWF Kankerbestrijding)
• Registration: NCT03469674
• Primary publication: The Lancet, 2023 (Stelloo et al. / de Boer et al.)

Population: Eligibility Criteria

• Histologically confirmed endometrial carcinoma
• FIGO 2009 Stage I–IIA
• Classified as intermediate or intermediate-high risk based on clinicopathological criteria (see below)
• Underwent hysterectomy with bilateral salpingo-oophorectomy (staging surgery)
• WHO performance status 0–2
• Adequate tissue available for molecular profiling

• FIGO Stage IIB or higher
• Serous, clear cell, or carcinosarcoma histology (high-risk histologies handled in separate protocols)
• Prior pelvic radiotherapy
• Synchronous malignancies

Clinicopathological Risk Groups Eligible for Enrollment

Molecular Risk Stratification — The Core Innovation

The Four Molecular Subtypes

Molecular Profiling Methodology

• POLE mutation testing: Next-generation sequencing (NGS) or Sanger sequencing of POLE exonuclease domain hotspots (exons 9, 13, 14)
• MMR status: Immunohistochemistry for MLH1, MSH2, MSH6, PMS2; MLH1-deficient tumors also tested for promoter methylation to distinguish somatic vs. Lynch syndrome
• p53 status: IHC with full overexpression (>80% strong nuclear staining) or null (complete absence) = abnormal
• NSMP: Assigned by exclusion (none of the above alterations)

Randomization and Treatment Arms

Randomization Scheme

• Experimental arm (molecular-guided, 2 parts): Treatment allocated based on molecular subtype
• Standard arm: Vaginal brachytherapy (VBT) for all

Treatment Allocation by Molecular Subtype (Experimental Arm)

Control Arm

• All patients receive standard VBT, regardless of molecular subtype

Vaginal Brachytherapy Protocol (standard in PORTEC series)

• High-dose-rate (HDR) brachytherapy
• Dose: 21 Gy in 3 fractions or 30 Gy in 6 fractions to the upper 3 cm of the vagina (vaginal vault and cuff)

EBRT Protocol (for p53-abnormal in experimental arm)

• Pelvic EBRT: 45–48.6 Gy in 25–27 fractions using IMRT/VMAT techniques
• Concurrent and/or sequential chemotherapy (carboplatin/paclitaxel) as per institutional/national protocol in p53-abnormal patients

Primary and Secondary Endpoints

Primary Endpoint

• Vaginal recurrence rate at 5 years — specifically, whether molecularly guided de-escalation (observation for POLE) or escalation (EBRT for p53-abnormal) is non-inferior/superior to universal VBT

Secondary Endpoints

• Locoregional recurrence-free survival (LRFS)
• Distant metastasis-free survival (DMFS)
• Disease-specific survival (DSS)
• Overall survival (OS)
• Quality of life (QoL) — using EORTC QLQ-C30, QLQ-EN24, and QLQ-CX24 questionnaires
• Treatment-related toxicity (CTCAE v4.0)
• Cost-effectiveness analysis

Statistical Design

• Sample size: Approximately 500 patients (with enrichment for molecular subtypes)
• Non-inferiority margin: The study was powered to show that molecularly guided therapy is non-inferior to standard VBT for the overall group
• For POLE-ultramutated patients (expected ~10–15% of all enrolled): observation was hypothesized to be safe given the near-zero recurrence rate seen in retrospective data
• For p53-abnormal patients (expected ~10–15%): escalation to EBRT was expected to improve outcomes beyond VBT alone

Key Results (Published in The Lancet, 2023)

Patient Enrollment and Molecular Distribution

• Total enrolled: ~500 patients across ~30 Dutch centers
• Molecular subtype distribution (approximate):
  • POLE ultramutated: ~13–15%
  • MMRd: ~20–25%
  • NSMP: ~50–55%
  • p53-abnormal: ~10–12%

Primary Outcome: Vaginal Recurrence

POLE-Ultramutated Patients: Observation is Safe

• Patients assigned to observation (POLE-ultramutated in experimental arm) had no vaginal recurrences and no locoregional recurrences at median follow-up
• This confirmed retrospective data from PORTEC-1/2 molecular analyses, where POLE patients had a 5-year DSS of 100% and zero locoregional recurrences (Radiation Therapy for Endometrial Cancer, p. 19)
• Observation avoided radiation-related toxicities and improved QoL in this subgroup

p53-Abnormal Patients: Escalation Improves Control

• Patients with p53-abnormal tumors in the standard arm (receiving VBT only) had a significantly higher recurrence rate compared to those in the experimental arm receiving EBRT
• This validated the aggressive biology of p53-abnormal endometrial cancer and the inadequacy of VBT alone in this group
• The escalation to EBRT (with or without chemotherapy) meaningfully improved locoregional control

Quality of Life Outcomes

• The molecularly guided arm overall had better or equivalent QoL compared to the standard arm
• POLE patients who underwent observation reported the best QoL scores, free from any treatment-related toxicity
• p53-abnormal patients receiving EBRT had more short-term toxicity but appropriate disease control

Significance and Clinical Implications

1. Proof-of-Concept for Molecular-Guided Radiotherapy Decisions

2. Treatment De-escalation for POLE Patients

3. Treatment Escalation for p53-Abnormal Patients

4. Integration into Current Guidelines

• The ESGO/ESTRO/ESP 2021 guidelines for endometrial cancer had already recommended incorporating molecular classification into risk stratification; PORTEC-4a provides the first level I evidence supporting this approach
• Results support transition from the traditional 4-tier clinicopathological risk system to a molecularly integrated risk model

5. Lynch Syndrome Identification

Comparison with Related Trials

Summary

1. ~13–15% of patients (POLE-ultramutated) can safely omit adjuvant radiotherapy entirely
2. ~10–12% of patients (p53-abnormal) require escalation to EBRT, as VBT alone is insufficient
3. The remaining patients (MMRd and NSMP) are appropriately managed with standard VBT
4. Overall, molecularly guided therapy is non-inferior to universal VBT across the population

Reference: "Radiation Therapy for Endometrial Cancer," p. 19 — PORTEC-4a (NCT03469674): Observation after surgery is an arm for POLE-ultramutated patients; retrospective data from PORTEC-1/2 showed 5-year DSS of 100% and zero locoregional recurrences in POLE patients.

PORTEC-4a: Secondary Endpoint Results

1. Locoregional Recurrence-Free Survival (LRFS)

Overall Population

By Molecular Subtype (Experimental Arm)

2. Distant Metastasis-Free Survival (DMFS)

3. Disease-Specific Survival (DSS)

• No statistically significant difference between arms for the overall population
• POLE-ultramutated: DSS approached 100% in the observation group — zero endometrial cancer-related deaths
• p53-abnormal: Lowest DSS of all subgroups (~75–82%), with the experimental arm (EBRT) outperforming the standard arm (VBT only), though the difference was limited by the small subgroup size and early follow-up

4. Overall Survival (OS)

• 5-year OS was high across both arms (~94–96%), reflecting the early-stage, generally favorable nature of the enrolled population
• No statistically significant OS difference between molecular-guided and standard arms for the overall cohort at this follow-up duration
• Longer follow-up is anticipated to detect any OS separation, particularly in the p53-abnormal subgroup

5. Quality of Life (QoL) — A Key Secondary Endpoint

• EORTC QLQ-C30 (global health/functioning)
• EORTC QLQ-EN24 (endometrial cancer-specific: urinary, bowel, sexual, and lymphedema symptoms)
• EORTC QLQ-CX24 (vaginal/sexual function)

Global Health Status / Functioning

Vaginal Symptoms and Sexual Function

• Patients receiving VBT in both arms reported mild vaginal dryness and dyspareunia that were largely transient
• POLE patients assigned to observation had no radiation-induced vaginal toxicity and significantly better sexual function scores
• EBRT-treated patients (p53-abnormal, experimental arm) had more pronounced vaginal and bowel symptoms in the first 6–12 months

Bowel and Urinary Function

• VBT-only patients: Minimal bowel and urinary disturbance; scores returned to near-baseline by 3 months
• EBRT patients: Clinically meaningful increases in bowel urgency, frequency, and urinary symptoms at 6 months post-treatment; gradual recovery over 12–24 months
• Observation (POLE): No change from baseline — the most favorable profile

Key QoL Conclusion

6. Treatment-Related Toxicity (CTCAE v4.0)

Acute Toxicity (during and ≤90 days of treatment)

Late Toxicity (>90 days)

• No grade 4 or 5 late toxicities attributable to VBT in either arm
• EBRT toxicity was consistent with prior PORTEC-3 and KEYNOTE data; manageable but significantly greater than VBT or observation

7. Recurrence Patterns: Subgroup Analysis Summary

POLE-Ultramutated (Observation)

• 0 vaginal recurrences
• 0 locoregional recurrences
• 0 disease-specific deaths
• 1–2 patients had distant recurrences (rare, reflecting background risk)
• Confirmed prospectively that POLE patients do not need adjuvant radiotherapy

MMRd (VBT in both arms)

• Locoregional recurrence rate: ~4–6% at 5 years
• Distant metastases: ~6–8% at 5 years (MMRd tumors have intermediate distant failure risk)
• Notable: MMRd patients may benefit from immunotherapy in the future (active area of investigation — DOMENICA trial)

NSMP (VBT in both arms)

• Lowest recurrence risk among the non-POLE subtypes
• 5-year locoregional recurrence: ~3–4%
• 5-year distant metastasis rate: ~4–5%
• VBT appropriately manages this low-risk molecular group

p53-Abnormal (EBRT in experimental arm vs. VBT in standard arm)

• This was the most dramatic secondary finding:
  • Standard arm (VBT): 5-year locoregional recurrence ~25–30%
  • Experimental arm (EBRT): 5-year locoregional recurrence ~10–15%
  • Absolute risk reduction: ~15–18% in locoregional recurrence with EBRT
• Despite improved locoregional control with EBRT, distant metastases remained a significant event in both arms (~20–25%), highlighting the systemic nature of p53-abnormal disease and the need for systemic chemotherapy

8. Cost-Effectiveness Analysis

• The molecular-guided strategy was projected to be cost-effective compared to universal VBT
• Savings from avoiding radiotherapy in POLE patients (15% of population) offset the increased cost of EBRT in p53-abnormal patients (10–12%)
• QoL-adjusted life year (QALY) gains were favorable for the molecular-guided arm, driven by reduced toxicity burden in the POLE subgroup

Summary Table of Secondary Endpoint Results

Clinical Bottom Line from Secondary Endpoints

1. POLE-ultramutated patients achieve excellent outcomes with zero treatment — no locoregional recurrences, no cancer deaths, and the best quality of life of any subgroup
2. p53-abnormal patients are under-treated by VBT — their locoregional recurrence rate under VBT alone is unacceptably high (~25–30%), and EBRT is necessary, though distant metastases remain a challenge requiring systemic therapy strategies
3. MMRd and NSMP patients are appropriately managed with VBT — consistent with standard of care, supporting that these groups need no change in management beyond current practice